Two days after showing strong pediatric cancer data, Day One taps $150M in public capital

Public biotechs can still raise money, but it comes with a big caveat: the clinical data must impress.

It appears the market reacted so with Day One Biopharmaceuticals, as the biotech plans to secure $150 million this week in a public offering. The four-year-old company is following a trend of biotechs going straight to the market hours or days after releasing results that outperform expectations and pad the case for a drug’s potential regulatory path.